NCT03472651View on ClinicalTrials.gov

Bioequivalence Study to Compare Two Formulations of Deanxit®

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Healthy
Interventions
DRUG

test treatment: flupentixol/melitracen

0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose

DRUG

reference treatment: flupentixol/melitracen

0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose

Trial Locations (1)

Unknown

CN1036 Shijitan Hospital, Beijing

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03472651 - Bioequivalence Study to Compare Two Formulations of Deanxit® | Biotech Hunter | Biotech Hunter